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Recently, it was reported that lower serum uric acid (UA) in hemodialysis patients 
correlated with unfavourable outcomes (Beberashvili, I. et al.,2015). In general, 
hyperuricemia aggravates cardiovascular disease (CVD) and chronic kidney disease 
(CKD) progression. In chronic kidney disease, higher serum UA levels accelerate the 
deterioration of kidney function (Latif, W. et al., 20119; Kanby, M. et al., 2011; Chonchol, 
M. et al., 2007). A recent randomized trial of allopurinol for CKD and CVD events reported 
reduced progression of renal disease and reduced CV risk in CKD patients treated with 
allopurinol (Goicoechea M, et al, 2015). Possibly because of the extra UA lowering effect 
of xanthine oxidoreductase (XOR) inhibitors (XORi). This study investigated the 
relationship of baseline serum UA with outcomes, controlling for confounding factors, 
and estimated whether XOR inhibition improved the all-cause mortality. Xanthine 
oxidoreductase (XOR) catalyzes the conversion of hypoxanthine to xanthine and 
xanthine to uric acid with concomitant reduction of either NAD+ or O2. XOR was 
discovered approximately 100 years ago and xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO) conversion were discovered approximately 30 years ago (Bray 
RC et al., 1988). In vivo, XDH preferentially reacts with NAD+, whereas XO cannot, but 
in the pathological condition, produces the superoxide anion (O2−) and hydrogen 
peroxide (H2O2) (McCord JM et al., 1985; Saugstad OD et al.,1988; Hille R et al., 1995; 
Bender D et al., 2018; Nishino T et al., 2008). It is well established that O2− and H2O2 
cause tissue damage (Biscaglia S et al., 2016). XO expression is upregulated by ATP 
degradation caused by certain pathological conditions such as ischemia, hypoxia, and 
oxidative stress, triggered by cellular stress. Under these pathological conditions, ATP is 
metabolized to hypoxanthine, xanthine, and uric acid via reactions catalyzed by XO 
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(Johnson RJ et al., 2013). XO produces reactive oxygen species (ROS) such as 




Study Population: This study included 2429 hemodialysis patients who were outpatients 
treated in 30 hemodialysis clinics in Yokohama Japan, between April 1, 2013 and March 
31, 2016 
Outcomes: The primary outcome of this study was all-cause mortality. The secondary 
outcome was CVD event (ICD-10 codes I00.0-I99.0) from the World Health Organization 
ICD-10.  
Statistical Analysis: We fitted the Cox proportional hazard model for the mortality and 
CVD outcomes. Covariates were demographic and comorbidities data along with 
baseline serological markers.Marginal structural model : We created a marginal 
structural model (MSM) to estimate the treatment effect of XORi on mortality and CVD 
events, reasoning that prescribing decisions are influenced by serological parameters 
from the previous visit and past prescription patterns (Robins, J.M. et al., 2000 ). To 
adjust for the confounding effect of prescribing XORi, we calculated the inverse 
probability of treatment weighted (IPTW) estimates for XOR inhibition treatment at each 
monthly visit, 36 times for each patient.  
Results 
Cox Hazard Analysis: We performed Cox hazard analysis to estimate the correlation 
between baseline characteristics and mortality and CVD events. UA was not correlated 
with all-cause mortality or CVD events in the Cox model; however, the hazard ratio (HR) 
for mortality was 0.96 for the baseline administration of XORi. 
 Marginal Structural Model Analysis: We performed a marginal structural model (MSM) 
analysis for this longitudinal repeated measure analysis to estimate the treatment effect 
of XORi on hemodialysis patients, according to the method of Robins and Hernan. The 
treatment effect of XOR inhibitors, estimated by MSM with stabilized weight for all-cause 
mortality, was associated with an HR of 0.24 (95% CI 0.15 - 0.38). The treatment effect 
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of XORi on CVD events was associated with an HR of 0.92 (95% CI 0.76–1.12) . 
Discussion  
We estimated an HR of 0.23 for all-cause mortality in patients receiving XOR inhibitor in 
this 3-year follow up study using observational MSM. MSM was used in the study to 
analyse repeated measured data and each visit and each patient was adjusted by using 
inverse probability of treatment weighted (IPTW) estimates with 2429 cases and 36 visits. 
To estimate the effect of XOR inhibitor in hemodialysis, serum uric acid level alone should 
not be considered suitable as a marker of hyperuricemia. Ives et al. reported that XOR 
elevate reactive oxygen species (ROS) and not by UA. Macrophage secretion of 
interleukin (IL)-1 beta is rapidly mediated by XOR activation, while XOR inhibition impairs 
IL-1 beta secretion (Ives A et al., 2015). Yisireyili et al. reported that febuxostat decreased 
ROS production (H2O2 and 8-OHdG and lipid peroxidation) and visceral adipose tissue 
inflammation in stress-induced hyperuricemic mice (Yisireyili M. et al., 2017). This MSM 
analysis also indicated that XOR inhibition reduced new onset of uncontrolled 
hypertensive diseases, suggesting that XOR inhibition can act directly on the systemic 
vascular wall. The recommendation from our study is that a higher dose of XORi should 
be used in the higher serum UA level group and also in lower UA level groups with high 
oxidative stress due to malnutrition, severe lower leg arteriosclerosis, or aspiration 
pneumonia. Improved nutritional status leads to a more favorable outcome in the lower 
serum UA group, and we recommended XORi administration even when the UA is 
approximately 6.0 mg/dL. In hemodialysis patients, it has been recommended to lower 
UA to the same level as in CKD patients, and that a further XOR inhibitory effect has an 
anti-inflammatory effect rather than an effect resulting from UA lowering. This study did 
not estimate the effect of UA lowering, but rather evaluated the effects of XOR inhibition 
on mortality due to CVD events. In this repeated measured analysis, XOR inhibition was 
estimated to improve all-cause mortality and CVD events in end stage renal disease. 
The true therapeutic goal of treatment with XORi is reduction of underlying oxidative 
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